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Abstract
Boronic acids, known to bind diols, were screened to identify non-inflammatory cross-linkers for the preparation of glucose
sensitive and insulin releasing agglomerates of liposomes (Agglomerated Vesicle Technology-AVT). This was done in order
to select a suitable replacement for the previously used cross-linker, ConcanavalinA (ConA), a lectin known to have both
toxic and inflammatory effects in vivo. Lead-compounds were selected from screens that involved testing for inflammatory
potential, cytotoxicity and glucose-binding. These were then conjugated to insulin-encapsulating nanoparticles and
agglomerated via sugar-boronate ester linkages to form AVTs. In vitro, the particles demonstrated triggered release of
insulin upon exposure to physiologically relevant concentrations of glucose (10 mmoles/L–40 mmoles/L). The agglomerates
were also shown to be responsive to multiple spikes in glucose levels over several hours, releasing insulin at a rate defined
by the concentration of the glucose trigger.
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Introduction
The development of glucose-responsive controlled insulin delivery
systems has attracted much attention due to its potential application
inmaintainingnormalbloodglucoselevels,oneofthekeygoalsofthe
treatment of Type 1 diabetes [1]. Several self-regulated insulin
delivery systems have been developed in recent years. These include
polymers with sugar binding functional group (e.g. ConA, Phenyl-
boronic acid)whichform complexes withdiolsand polyols inaqueous
environment [2,3]. The critical solution behavior (e.g. LCST: lower
critical solution temperature) of the polymers have been shown to
change with environmental variations in glucose concentrations.
Insulin is loaded with the polymers, and released, when the
hydrophilicity of the complex is increased, due to the high-affinity
binding of the glucose-responsive group to free glucose [3,4]. Other
types of delivery vehicles being explored are hydrogels containing
chemically modified insulin, with glucose moieties binding to ConA
or similar lectin, which can be dissociated when exposed to increasing
concentrations of glucose thereby releasing the insulin [5,6] and
closed loop insulin delivery systems which contain a continuous
glucose monitoring device that measures blood glucose concentra-
tion, a control algorithm to calculate the amount of insulin to be
delivered, and an insulin pump. The route of insulin administration
depends on whether the system is extracorporeal (subcutaneous
monitoring and delivery) or implanted (intravenous monitoring and
intraperitoneal delivery) [7].
Our group has previously advanced a platform technology for
glucose responsive insulin delivery, the AVT or agglomerated
vesicle technology. AVT is a chemically cross-linked agglomerate
of liposomes loaded with insulin [8]. The cleavage of the chemical
cross-links is tunable and can be triggered by the endogenous
glucose concentration [9]. Thus, hyperglycemic events are quickly
restored to euglycemic levels by cleaving of the cross-links followed
by release of insulin encapsulated within the liposomes. Since the
cleaving agent is endogenous glucose itself, the amount of insulin
released is directly dependent on the blood glucose concentration
and is halted soon after reaching normoglycemia, thereby avoiding
the risk of hypoglycemia. Preliminary in vivo studies have been
reported in previous studies from our group, establishing the drug
release characteristics and stability of the AVTs [9,10]. However,
the major shortcoming of these AVT particles is that the glucose-
sensitive linkage is based on competitive binding of ConA to a
sugar. ConA is a lectin with high affinity for glucose but is known
to be toxic [11]. To address this shortcoming we have carried out a
screening study and identified a small molecule linker which binds
to glucose with a binding constant similar to that of ConA but is
less toxic and has lower inflammatory potential.
Boronic acids are known to bind diols, including glucose,
fructose etc., reversibly, to form stable mono- and bisdentate
complexes [12,13,14]. The saccharide binding property of boronic
acids has prompted their use as sugar recognition moieties in
glucose sensors [15,16,17] and self-regulated insulin delivery
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to synthesize a boronic acid functionalized liposome which in turn
can bind to glucose functionalized liposomes, thereby forming
glucose-cleavable AVTs. Our goal therefore, was to identify
compounds that could bind to a wide variety of sugars with a
range of binding constants, both above and below that of glucose,
so that the AVT particles are capable of cleaving over a broad
range of glucose concentrations. Further, in vivo use of an AVT
particle based on this compound would require that the compound
(and the resulting particle) have low toxicity and inflammatory
potential. In this study therefore, as a first step to this goal, we
screened a large number of boronic acid derivatives for their
toxicity and inflammatory properties and identified lead com-
pounds that could safely be used in vivo. Nuclear translocation of
NF-kB was used as an indicator of the inflammatory potential of
the boronic acids. NF-kB is a widely studied transcription factor
which plays a key role in inflammatory response [19]. The NF-kB
family includes the following proteins: RelA(p65), RelB, RelC
(cRel), NF-kB1 (p50 and p105) and NF-kB2 (p52 and p100) [20].
Under normal conditions the RelA-p50 heterodimers are present
in the cytoplasm, bound to proteins of the IkB family. Upon
stimulation by a wide range of stimuli such as tumor necrosis
factor a (TNFa), interleukin 1 (IL1) or other pro-inflammatory
species, the IkB proteins are phosphporylated by the IKK
complex. This leads to release and subsequent nuclear transloca-
tion of the RelA-p50 dimers. The translocated RelA-p50 dimers
activate the transcription of various inflammatory cytokine genes
(eg. IL8, IL12 etc.). The nuclear translocation of NF-kB occurs
within the first 30–60 mins of exposure to a pro-inflammatory
species and is an early prognosticator of the downstream cascade
of events. Therefore, measurement of nuclear translocation of NF-
kB, upon exposure to a test species, provides an early and sensitive
indication of its inflammatory potential.
The sugar binding affinities of the lead compounds were
compared with those of ConA to identify a suitable replacement
for use in the next generation of AVT particles. The steps involved
in the screening process are summarized in Figure 1.
After completion of the screening, several boronic acids, mainly
belonging to two structural families, were identified as lead
candidates for replacing ConA. The selected candidates were
incorporated on the surfaces of liposomes, and used as a
replacement of ConA for synthesizing insulin loaded AVTs. The
in vitro insulin release profiles of the boronic acid-AVTs were also
tested and compared with that of the ConA-AVT.
Results
Selection of Boronic acids for screening
The first step in the screening process was a computational
clustering to select bi-functional boronic acid compounds with
reactive side chains for conjugation with lipid molecules. This was
necessary to identify boronic acids which can be used to
functionalize the insulin loaded liposomes and covalently link
them with other liposomes which have sugar molecules on their
surface.
A boronic acid library of 469 compounds was clustered into 150
groups using the number of rings and the number of aromatic
rings as criteria and applying the Extended Connectivity
Fingerprint algorithm with 4 bond layers (ECFP4) within Pipeline
Pilot [21,22]. The ECFPs account for the environment of every
atom in a molecule in an iterative way until a given threshold, thus
being able to essentially represent an infinite number of structural
features. For the numeric properties we chose ‘‘Number of Rings’’
and ‘‘Number of Aromatic Rings’’, since one of the goals was to
cluster the compounds based on the number of ring structures.
The cluster center selection parameter was set to Maximum
Dissimilarity and the Euclidean (RMS Distance) option was set as
the choice for the Numeric Distance Function parameter. The
Number of Clusters parameter was set to 150. The 150 clusters,
obtained using the process described above, were further
reclassified by visual inspection into two datasets of 76 (333
compounds) and 74 (136 compounds) clusters. This reclassification
was done in order to separate singletons or clusters containing
fused ring compounds. Only the first set was selected for further
development. From each cluster, one or more compounds were
visually selected, so as to maximize the diversity in terms of ring
type (benzyl or pyridyl), and number, position (ortho, meta, para)
and type of substituents. The final library of 110 test compounds
was then purchased from Sigma-Aldrich, MO.
The compounds in the library were further grouped as
derivatives of the following structural families:1)Phenylboronic
acid 2) Pyridine 3) Napthalene 4) Indole 5) Thiophene 6)
Thianthrene 7) Cyclopropyl 8) Pyrrole 9) Isoquinoline 10) Oxazole
11) Pyrazole and 12) Dibenzofuran.
Toxicity and inflammatory potential
Little is known about cytotoxic and inflammatory properties of
boronic acids. In this study we evaluated the inflammatory
potential and toxicity of the boronic acids selected from the
computational screening, using NF-kB translocation (PCC values)
and MTT assays (Cell surviving fraction) respectively. It was found
that majority of the compounds do not cause nuclear translocation
of NF-kB or substantial loss of cell survival, when exposed at the
lowest of the three doses (40 nM) that were tested. Any compound
that showed a positive PCC value at 40 nM and/or lower than
85% cell survival at the same were eliminated.
It was also observed that when used at the highest concentration
(160 nM), 50 out of the 70 compounds returned a PCC value over
0.1, indicating inflammation and 38 of them led to cell survival
fraction ,50%.
Hence, stress was given on the PCC values and surviving
fraction obtained when cells were treated with the intermediate
dose of 80 nM. (Representative images from the NF-kB nuclear
translocation assay are shown in Figure 2.) The criteria for
selection of compound were the following:
1) A PCC value #0.1 at 80 nM
2) Cell Surviving Fraction $80% at 80 nM.
The compounds listed below, belonging primarily to two
different structural families, were found to fulfill the selection
criteria outlined above and were chosen for the next step which is
binding affinity determination:
A) Phenylboronic acid derivatives
– 2,4-dichlorophenylboronic acid
– 4-aminocarbonylphenylboronic acid
– 3-N,N-dimethylphenylboronic acid
– 4-hydroxyphenylboronic acid
– 4-propylphenylboronic acid
– 4-chlorocarbonylphenylboronic acid
– 3-[(E)-2-nitrovinylphenylboronic acid
B) Pyridine and Pyrimidine boronic acid derivatives
– 2-bromopyridine-3-boronic acid
Glucose-Responsive Insulin Delivery System
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– 2,4-bis(benzyloxy)pyrimidin-5-boronic acid
Another boronate from this family, 2-bromopyridine-5-boronic
acid, also passed the selection criteria mentioned above. However
when compared with the closely related derivative, 2-bromopyr-
idine-3-boronic acid, the latter was found to have a much better
cell survival at 160 nM (88%) and was chosen instead.
In addition, three compounds that did not belong to either of
these families were selected. These were:
– cyclopenten-1-yl-boronic acid
– 5-phenyl-2-thienylboronic acid
– 5-formylthiophene-3-boronic acid.
Binding Assays
The binding affinity of the boronicacids to glucose was determined
by a competition assay using ConA, a known high affinity glucose
binder. The assay was initiated by immobilizing glucosemolecules on
the surface of activated magnetic beads, as described in the
methods.The binding reaction was carried out in a 96 well plate by
incubating the beads containing the glucose molecules on their
surface, with a fixed concentration of ConA-FITC (2.4 mM) and
increasing concentrations of the boronic acid being tested (2.5 mM–
20 mM). After completion of the reaction, the beads were washed to
remove excess unbound ConA-FITC and boronic acid. The
fluorescence intensity of the mixture was measured and used as an
indication of the amount of ConA-FITC bound to the glucose
molecules on the surface of the beads, or [ConAs]. The ConA-FITC-
glucose interaction is expected to be inhibited by boronic acid which
competes and binds to the glucosemolecules and displaces the bound
ConA-FITC, thereby causing a decrease in fluorescence intensity of
the mixture. The reduction of fluorescence intensity can be co-related
to [ConAs] by Equation 1, where Fmax is the maximal fluorescence
intensity (positive control; ConA-FITC only), Fobs is the observed
fluorescence intensity for the test wells.
ConAs ½  ~ 1{
Fmax{Fobs
Fmax
  
  ConAs ½ ð Eq:1Þ
The relationship between the amount of adsorbed ConA
([ConAs]) and the amount of boronic acids [BA] is given by
Equation2, where St is the concentration of glucose binding sites,
KaConA is the equilibrium constant for the binding of ConA-FITC
and glucose and KaBA is the equilibrium constant for binding of
Boronic acid and glucose.
ConAs ½  ~
St: ConA ½ 
1z
BA ½  :KaConA
ConA ½  :KaBA
ðEq:2Þ
Simple rearrangement yields Equation 3, from which the ratio
of the two equilibrium constants (KaConA/KaBA) can be derived
Figure 1. Flowchart describing the experimental screening and selection of boronic acid linker for insulin AVT.
doi:10.1371/journal.pone.0029585.g001
ð1Þ
ð2Þ
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~
1
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BA ½ 
ConA ½  St
 
KaConA
KaBA
ðEq:3Þ
The concentration of sugar sites (St) can be calculated from the
intercept of a plot of 1/[ConAs] vs. 1/[BA]. Figure 3 shows a
representative plot for the binding constant calculations. The
competition assay was carried out for all the thirteen compounds
selected from the toxicity and inflammation screen. Three of those
compounds did not show any competitive displacement of ConA-
FITC and were thus removed from the screen. Using the methods
described above, we could determine the binding constants for the
remaining ten boronic acids.
Selection of final leads
The results for the overall screening of the boronic acids
chemical library are summarized as a color intensity map in
Figure 4. The final leads, highlighted in blue, have the following
properties
1. Cell Surviving fraction
N 85% at 40 nM
N 80% at 80 nM
N 55% at 160 nM
2. Inflammatory potential, as indicated by PCC values.
N ,0a t4 0n M
N ,0.1 at 80 nM
N #0.3 at 160 nM
3. Sugar binding affinity relative to ConA, quantified by the log of
the ratio between the glucose binding constants derived for the
Boronic Acids (KaBA) and ConA (KaConA).
Figure 2. Effect of boronic acid treatment on the nuclear or cytoplasmic localization of NF-kB. Nuclear stain DAPI is shown in blue, while
the NF-kB is represented by green. Visible blue nuclei surrounded by green indicate cytoplasmic NF-kB, while obliteration of the blue by green signal
in the nucleus indicates nuclear NF-kB. (A) Untreated control, cytoplasmic NF-kB (B) Positive control, nuclear translocation of NF-kB in cells treated
with LPS, (C) Treatment with 2,4-ditertbutoxypyrimidine-5-yl-boronic acid (80 nM, 2 hrs.), predominantly cytplasmic NF-kB and (D) Treatment with 5-
isoquinoline-boronic acid (80 nM, 2 hrs.), predominantly nuclear NF-kB.
doi:10.1371/journal.pone.0029585.g002
Figure 3. Determination of binding affinity. [ConAs]=concentra-
tion of ConA-FITC adsorbed to sugar molecules on the surface of
magnetic beads., [ConA]=bulk concentration of ConA-FITC, [St]=Total
sugar sites available for binding of ConA-FITC, KaConA=Binding
constant of ConA and glucose, KaBA=Binding constant of boronic acid
and glucose; The ratio of KaConA and KaBA can be calculated multiplying
[St], [ConA] and the slope of the plot.
doi:10.1371/journal.pone.0029585.g003
ð3Þ
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These compounds can be broadly grouped into two structural
families: derivatives of phenylboronic acid with electron with-
drawing substituents and pyrimidineboronic acid. The binding
constants (Ka) for the six lead boronic acids are shown in Table 1,
along with the surviving cell fraction and correlation between
nuclear and cytoplasmic fractions of NF-kB when HeLa cells were
treated with these compounds.
Preparation of lipid-PEG-boronic acid and lipid-PEG-sugar
conjugates
To prepare liposomes functionalized with the lead compounds,
PEGylated lipid conjugates were synthesized and incorporated in
the liposomal formulation. The conjugation of the boronic acids
with lipid-PEG molecule is not expected to interfere with their
ability to bind glucose for the following reasons: (a) attachment to
the PEG moiety (which floats freely on the surface of the liposome
in the final formulation), is away from the B(OH)2 group involved
in complexation with the diols [14]; and (b) PEGylated boronic
acids have been shown to effectively bind glucose in hydrogel and
polymer based glucose sensing devices [23,24]. It should also be
noted that the boronic acids were not extensively PEGylated,
rather only a single lipid-PEG molecule was used per boronic acid.
Five amine functionalized boronic acids (Figure 5,compounds
7–11), with similar electronic properties as the lead compounds,
were selected for facile conjugation to the carboxyPEGylated lipid.
Each was allowed to react with DSPE-PEG-COOH under
carbodiimde conditions as shown by the example in Scheme S1.
In a similar manner, amine derivaties of glucose (12), galactose (13)
and mannose (14) were also conjugated to DSPE-PEG-COOH
under similar conditions (Scheme S2), and used in the formulation
of sugar coated liposomes.
The inflammatory potential and toxicity of these newly
synthesized lipid-PEG-boronate conjugates were also assayed
and the results are shown in Figure 6A and 6B. One of the
compounds, 3-fluoro-4-aminomethylphenylboronic acid caused
enhanced toxicity whereas 4-aminocarbonylphenylboronic acid,
showed higher cell survival rates and lower inflammatory potential
than it’s non-conjugated form.
Figure 4. Heat map showing the Cytotoxicity (MTT), Inflammation (PCC) for all the boronic acids. Relative Sugar binding affinities,
compared to ConA, are shown for compounds selected from the first two screening steps.The final leadsselected compounds are highlighted in blue.
doi:10.1371/journal.pone.0029585.g004
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Insulin
Synthesis of boronic acid-AVTs. Two different types of
liposomes (sugar linked and boronic acid linked) were prepared as
described in the methods section. A 40 mol% concentration of
cholesterol was added to the lipid bilayer. The cholesterol is known
to broaden the pretransition and main phase transition of DPPC
bilayers [25,26]. This ensures that the membrane is only softened
at physiological temperature (,37uC) and does not undergo a
sharp melting transition. These were co-incubated to form
agglomerates. The optimal conditions for agglomeration (molar
excess of the boronic acid liposome relative to the sugar liposomes,
pH and incubation time) were different for each one of the
boronate-AVTs as shown in Table 2. The results indicate that
these boronic acids are capable of forming the cross-links under
near physiological pH.
To confirm that the AVTs were formed by chemical cross-
linking of the boronic acid and sugar moieties, the agglomerates
were exposed to 10 mM glucose. The agglomerates were readily
cleaved in the presence of glucose, due to competitive binding of
the boronic acids with the free glucose. This was demonstrated by
the increase in fraction of particles sized under 1 mm from 13% to
37% upon incubation with glucose.
In vitro release of Insulin from the boronic acid-
AVTs. A small volume (500 mL) of the boronate-AVT was
loaded inside a tubular dialysis membrane (100 K MWCO),
sealed with clips, and dialyzed against a PBS solution (pH 7.4) for
60 mins to monitor the passive release of insulin without trigger.
Aliquots were removed from the external phase at regular intervals
and insulin concentration was assayed by reading the absorbance
at 214 nm. Figure 7 shows the cumulative release of insulin from
all of the boronate-AVTs listed in Table 2. The AVTs synthesized
with the boronic acids containing strong electron withdrawing
groups (3-fluoro-4-aminomethylphenylboronic acid and 5-amino-
2,4-difluorophenylboronic acid) were found to release their insulin
content too rapidly. The 4-aminopyrimidineboronic acid AVT
showed one episode of rapid burst release and did not release any
insulin after that. The two lead candidates selected from this assay
were (a) 3-aminophenylboronic acid AVT and (b) 4-
aminocarbonylphenylboronic acid AVT releasing 12% and 16%
of their insulin content respectively. Out of these two, the 4-
aminocarbonylphenylboronic acid AVT was chosen as the final
lead based on our previous observation that the toxicity and
inflammatory potential of the parent compound is reduced upon
conjugation with PEGylated lipid (Figure 6A and 6B).
Insulin release from the lead AVT, upon addition of varying
concentrations of glucose trigger, was then assayed for several
hours. The trigger concentrations were chosen so as to mimic
blood glucose levels at normoglycemic and hyperglycemic
conditions. A control assay was also set up where the lead AVT
was triggered with PBS instead of glucose. The agglomerate
exhibits a burst release of insulin within 2 mins after introduction
of the glucose trigger (Figure 8A and 8B). The release rate slows
down over time until another dose of glucose is added, which
triggers a new episode of burst release. The minimum concentra-
tion of glucose required for cleaving the agglomerates and
releasing insulin is 10 mmoles/L, which corresponds to a blood
glucose level of 180 mg/dL. We did not observe a burst release of
insulin when the particles were triggered with glucose concentra-
tions analogous to hypoglycemia (5 mmoles/L, ,90 mg/dL) and
Table 1. Lead Boronic Acids.
Boronic Acid
Glucose Binding Affinity
(M
21) Cell Survival (80 nM) (%)
PCC
(80 nM)
4-aminocarbonylphenyl boronic acid 45 97 0.01
3-N,N-dimethylamino phenyl boronic acid 357 86 20.04
4-propylphenylboronic acid 303 202 20.07
2,4-dichlorophenyl boronic acid 58 81 0.09
4-hydroxyphenyl boronic acid 80 198 20.01
2,4-ditertbutoxypyrimidin-5-yl-boronic acid 608 90 0.03
The binding constants (M
21), HeLa Cell Survival (%)** and PCC** values for the lead boronic acids (** Values shown are for HeLa cells incubated for 2 hrs. at 37uC with
80 nM concentration of the compounds).
doi:10.1371/journal.pone.0029585.t001
Figure 5. Amine substrates employed in PEGylated lipid-boronics acid and sugars conjugate preparation.
doi:10.1371/journal.pone.0029585.g005
Glucose-Responsive Insulin Delivery System
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29585normoglycemia (7 mmoles/L, ,126 mg/dL), suggesting that the
AVTs are suitable for maintaining normal blood glucose levels
(Figure 8B). Also, the insulin release rate from these microparticles
is dependent on the glucose concentration, thereby making this
platform potentially useful in avoiding hyperinsulinemia and
corresponding hypoglycemia.
Discussion
In this work, we have screened a library of boronic acid
derivatives for toxic and inflammatory properties and identified a
lead candidate molecule and several other potential backups that
will be better suited for in vivo usage as an alternative to the
lectin,ConA,in a glucose-responsive, insulin releasing composite
microparticle delivery system, AVT [8,9]. The glucose binding
affinities of the boronic acids short-listed from the toxicity and
inflammation screen were also determined; to ensure selection of a
compound that is similar to ConA in terms of sensitivity towards
variations in glucose levels.The selected leads were re-evaluated
for inflammation and cytotoxicity after being conjugated with
PEGylated lipids, for incorporation into the liposomes. This was
done to ascertain that the inflammation and toxicity profile of the
single molecules were not perturbed by the lipid-PEG conjugation.
Surprisingly we found that some of the lipid-PEG conjugated
boronic acids were even less toxic and inflammatory compared to
their monomeric forms as shown in Figure 6.This is a critical
observation as chronic exposure to the AVTs from daily
subcutaneous injections may result in long term effects, and the
reduction in toxicity by lipid-PEG conjugation offers a promising
solution to this problem.
To establish that these particles can be used for building a
insulin delivery vehicle we have performed preliminary in vitro
release studies. Parent liposomes were fabricated to contain either
sugar (glucose, galactose and mannopyranside) or one of the lead
boronic acid molecules on the outer surface. The liposomal
formulations were mixed together at room temperature to induce
reversible ester formation between the boronic acid and the 1,2-
cis-diol moieties of the sugar molecules. This resulted in cross-
linking of the liposomes to form agglomerated vesicles (AVT). We
have shown that in vitro cleavage of the AVTs by 10 mmoles/L
glucose trigger can cause a burst release of insulin. This is followed
by a slow release over several hours without further glucose
stimulation. This basal release rate is a critically important
property of these particles. In the absence of a basal untriggered
release, the only release of drug will be in the event of a trigger.
The amount of drug residual in the delivered dose on any given
Figure 6. Effect of PEGylation on cytotoxicity and inflammatory potential of boronic acids. (A) Pearson’s Correlation Coefficient between
the nuclear and cytoplasmic fractions of NF-kB molecule in HeLa cells treated with the lead boronic acids [both as single molecule (black bars) and
conjugated to DSPE-PEG-COOH(dark gray bars)], (B) Surviving fractions of HeLa cells treated with the same compounds as in (a). UTC: Untreated
Control, LPS: Lipopolysachharide.
doi:10.1371/journal.pone.0029585.g006
Table 2. Optimal conditions for preparing boronic acid AVTs.
Boronic Acid Moiety Sugar Liposome: Boronic Acid Liposome (mole/mole) pH
3-aminophenylboronic acid 1:5 7.5
5-amino-2,4-difluorophenylboronic acid 1:5 8
4-aminocarbonylphenylnboronic acid 1:20 8
3-fluoro-4-aminomethylphenylboronic acid 1:10 8
doi:10.1371/journal.pone.0029585.t002
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the potential for significant carryover from day to day. This could
lead to dose-buildup, and catastrophic consequences. Thus, a
basal release rate, that will insure dose depletion in a given day,
regardless of triggering, is a critical requirement for these particles.
Indeed, a shortcoming of the ConA based particles shown in
Figure 9 is the absence of such a basal release rate.
The release rate however can be increased very quickly by a spike
in glucose concentration (Figure 8A and 8B). In vivo, this would
translate to the ability of the particles to control blood glucose levels
for long periods, in spite of periodic glucose excursions, thus
reducing the need for multiple daily injections. We have also
demonstrated that the system is capable of responding to severely
hyperglycemic [27] glucose levels of 30 mmoles/L and above
(Figure 9Aand9B).Thepatternofinsulinrelease issimilartothat of
the ConA AVTs (Figure 9). Further studies will be conducted to
optimize the insulin release from these boronic acid linked
liposomes both in vitro and in vivo. Current results indicate that
phenylboronic acidswith electronwithdrawing substituents atthe2-
and 4- positions of the phenyl ring form very leaky AVTs and are
notsuitablefortriggeredreleaseapplications(Figure7).Howeveran
interesting future study can be the use of the multiple lead
candidates identifiedfrom the screening efforts to prepare liposomes
with more than one boronic acid on their surface, (See Table 1),
differing in their affinity towards glucose. This will allow us to
prepare AVTs which areheld together by boronicacid-diollinkages
of varying strengths. The degree of AVT cleavage and the rate of
insulin release will then depend on the number of strong, weak and
moderate linkages present. This way the AVTs can be fine-tuned to
be sensitive to even minor fluctuations in glucose levels.
Figure 7. Cumulative release of insulin from boronate-AVTs in the absence of glucose trigger.
doi:10.1371/journal.pone.0029585.g007
Figure 8. In-vitro release of Insulin from Boronic Acid AVT. (A) Cumulative and (B) differential plots for release of insulin from 4-
aminocarbonylphenylboronic acid AVTs triggered with 5 mM, 7 mM and 10 mM glucose.
doi:10.1371/journal.pone.0029585.g008
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1) NF-kB assay for inflammation
The inflammatory potential of the compounds was studied by
measuring the nuclear translocation of NF-kB in HeLa cells by
immunocytochemistry and high throughput high content micros-
copy. 15000 HeLa cells were plated in 96 well plates the night
before the experiments. On the day of experiment the cells were
treated with the test compounds at three different concentrations
for 2 hrs. At the end of the incubation cells were washed with PBS
and were fixed in 4% paraformaldehyde for 15 mins and
subsequently permeabilized with 0.01% Triton X-100 in PBS
for 10 mins. The cells were washed with PBS 3 times. Nonspecific
sites were blocked with 5% BSA in PBS and then incubated with
anti-NF-kB (Rabbit polyclonal NF-kB p65(C-20), Santa Cruz
Biotechnology, HInc.,Santa Cruz, CA) for 1 hr followed by
incubation with FITC-labeled secondary antibody (Goat a-rabbit
IgG-FITC labeled, Santa Cruz Biotechnology, HInc., Santa Cruz,
CA). After washing the cells at the end of the incubation they were
treated with DAPI for 1 min and kept at 4uC until further analysis.
Images of the cells were acquired with a Beckman-Coulter IC 100
automated high-throughput microscope system and analyzed
using Cyteseer software (Vala Sciences, San Diego, CA) [28,29].
The co-localization of NF-kB was quantified by measuring the
Pearson’s correlation coefficient (PCC) between the nuclear and
cytoplasmic fraction of the NF-kB molecule. The PCC is a
measure of the overlap between the pixel intensities of the nuclear
and cytoplasmic NF-kB images of the same cell, and is calculated
as [30]:
r~
P
i (xi{X)(yi{Y)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
i (xi{X)
2 P
i (yi{Y)
2
q ðEq:4Þ
Where xi and yi are the individual pixel intensities correspond-
ing to the nuclear and cytoplasmic NF-kBfluorescence, respec-
tively; X, Y are the corresponding mean intensities. The PCC
values can range from 21 to 1. A positive correlation (positive
PCC value) indicates nuclear translocation of NF-kB. A negative
correlation (negative PCC value) indicates an absence of nuclear
translocation [30].
2) MTT assay for cytotoxicity
The cytotoxicity of the compounds was studied by MTT assay.
15000 HeLa cells were plated in 96 well plates on the night before
the experiment. On the day of experiment the cells were treated
with the test compounds at three different concentrations for 2 hrs.
At the end of the incubation MTT assays (In vitro toxicology MTT
based assay kit, Sigma-Aldrich, MO) were performed according to
the manufacturer’s protocol.
3) Binding assay
Thebindingaffinityoftheboronicacidstoglucosewasdetermined
by a three component –competitive assay which includes a
fluorescently labeled ConA, Boronic Acids and Glucose. Glucose
molecules were immobilized on a solid support using the following
method: Carboxy terminated magnetic beads(Bangs Laboratories,
Inc., Fisher, IN) were activated by suspending them in 100 mM MES
buffer (pH 4.5) and aliquoted (100 ml/well) in 96 well plates. The
activated beads were conjugated to amine terminated glucose
molecules (100 mg/ml), D-(+)- glucosamine (Sigma-Aldrich, MO)
[31] using EDC as a cross linker. The cross-linking reaction was run
for 24 hr, at room temperature on an orbital shaker, and after
completion the beads were separated by placing the microplate on a
magnetic separator and washed thoroughly with PBS at pH 7.2 to
remove unbound glucose, excess EDC and Sulfo-NHS.
The competitive binding, between ConA and Boronic acid, was
then carried out as follows:
The magnetic beads, decorated with glucose molecules on their
surface as described above,were then co-incubated for 1 hour with
varying concentrations of the boronic acid (2.5 mM–20 mM) being
tested and a fixed concentration of fluorescently tagged ConA,
2.4 mM (ConA-FITC, Sigma Aldrich, MO). Non-conjugated
magnetic beads were treated with ConA-FITC to determine
non-specific binding. Maximal binding was determined by treating
glucose conjugated beads with ConA-FITC only.
The beads were washed 3 times with PBS at pH 7.2 to remove
unbound boronic acids and ConA-FITC and resuspended in PBS
and stirred for 15 mins at room temperature before measuring FITC
fluorescence (excitation: 495 nm, top emission: 520 nm; 6 flashes per
well; average of n=3 wells) in a Flexstation II
384 microplate reader
(Molecular Devices, Inc., Sunnyvale, CA) to quantify the amount of
glucose bound to the boronic acids.
Figure 9. In-vitro release of Insulin from Boronic Acid and ConA AVTs. Cumulative and differential plots for insulin release from 4-
aminocarbonylphenylboronic acid AVT and ConA AVTs triggered with 10 mM, 30 mM and 40 mM glucose.
doi:10.1371/journal.pone.0029585.g009
ð4Þ
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All lipid-PEG-linker-boronic acid conjugates were prepared by
coupling the amine-derivative of the boronic acid-linker (Figure 5),
with DSPE-PEG-COOH [1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-(carboxy(polyethylene glycol)-2000), Avanti
Polar Lipids, Inc., Alabaster, AL] using carbodiimide chemistry.
3-aminophenylboronic acid (7) was obtained from Sigma-Aldrich,
St. Louis, MO; 3-fluoro-4-aminomethylphenylboronic acid (9), 5-
amino-2,4-difluorophenylboronic acid (8) and 4-aminopyrimidine-
boronic acid (10) boronic acids were obtained from Combi-Blocks,
Inc., San Diego, CA;. 3-aminopropyl tethered 4-aminocarbonyl-
phenylboronic acid (11) was prepared in-house from 4-bromoben-
zoyl chloride and N-Boc-1,3-propanediamine in three steps. The
NMR spectra are shown in Figues S1, S2 and S3.
In general, 50 mg of DSPE-PEG-COOH were dissolved in 2 ml
anhydrous DMF (Sigma Aldrich, St. Louis, MO) followed by the
addition of EDC (Pierce, Rockford, IL) (2.0 equivalents) and NHS
(Pierce, Rockforfd, IL) (3.0 equivalents), and the mixture stirred for
30 mins at room temperature. The amine derivative of the boronic
acid (2.0 equivalents) was then added and the reaction mixture stirred
overnight. Amines obtained in the form of the ammonium salt, were
desalted by stirring in 500 mLD M Fa n d3 5mL triethylamine (Sigma
Aldrich, St. Louis, MO) for 30 mins at room temperature prior to
addition to the reaction mixture. The reaction mixture was then
diluted with 4 mL MES buffer (50 mM, pH 4.18), transferred into a
2 K MWCO dialysis cassette (Pierce, Rockford, IL) and dialyzed
twice against 2 L of the same buffer, then twice against 2 L water
followed by freeze drying to obtain the desired conjugates.
The lipid-PEG-sugar species were synthesized by conjugating the
carboxyl group of DSPE-PEG-COOH to the amino group of
glucosamine (12), galactosamine (13), and mannopyranoside (14)
(Fisher Scientific, Houston, TX) (Figure 10), using the same protocol.
5) Synthesis of Liposomes functionalized with sugar/
boronic acids and their agglomeration:
AVT particles with Sugar-ConA linkages were prepared
using the following method. Human recombinant insulin
(Sigma Aldrich, St. Louis, MO) was dissolved in Citrate Buffer
(100 mM, pH 2.5) to a concentration of 15 mg/ml. The
phospholipids DPPC (1,2-diplamitoyl-sn-glycero-3-phosphatidyl-
choline) and Cholesterol were purchased from Lipoid GMBH,
Ludwigshafen, Germany. Lipids (56.4 mole% DPPC, 40 mole%
Cholesterol and 1.2 mole% each of DSPE-PEG-Glucose, DSPE-
PEG-Galactose and DSPE-PEG-Mannopyranoside) were
dissolved in ethanol and hydrated with the insulin solution at
50uC for 15 mins. The final lipid concentration was 50 mM. The
hydrated mixture was then passed 8 times through a 400 nm
Nucleopore track-etch membrane at 50uC and a pressure of
100 psi.The parent liposomes had a mean diameter of
244.160.1 nm and a lipid concentration of 50 mM. Insulin was
encapsulated inside the liposomes by passive loading. The pH of
the liposomal formulation was maintained at 5.6 (isoelectric point
of insulin). The liposomes were dialyzed against citrate buffer
(100 mM, pH 5.6) to remove the unencapsulated insulin.The pH
of the formulation was then raised to 6.6 and 3 mM CaCl2/3 mM
MnCl2 were added for optimal binding of ConA. An aliquot of
ConA solution (pH 6.6, with 3 mM CaCl2, 3 mM MnCl2) was
added to the liposomal formulation at a 2:1 molar ratio over the
glycosyl species present in the outer leaflet of the lipid bilayer. The
agglomeration process was completed in 10 mins.
AVT particles with boronic acid linkages were prepared
using the following method. Lipid-PEG-boronic acid was
synthesized by conjugating the carboxyl group of DSPE-PEG-
COOH to the amine functionalized boronic acids using the
carbodiimide coupling chemistry as described earlier. The lipid
Figure 10. The final structure of DSPE-PEG-Sugar conjugates.
doi:10.1371/journal.pone.0029585.g010
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following: (56.4 mole % DPPC, 40 mole% Cholesterol and
3.6 mole% of DSPE-PEG-boronic acid). The insulin loading,
extrusion and purification processes were similar to that used for
the sugar liposomes as described above. The liposomes had a
mean diameter of 18460.162 nm.
Preparation of AVT. Two kinds of insulin loaded liposomal
formulations, functionalized either with sugar molecules or a
boronic acid derivative, were mixed and stirred at room
temperature to form agglomerates. The mixtures were prepared
using several molar ratios of sugar species to boronic acid species,
ranging from 1:2 to 1:50, to determine the optimal excess of
boronic acids required for agglomerate formation. The pH of the
mixture was also varied between 7 and 11, the range in which
boronic acids are known to bind diols [14], in order to select AVTs
that are preferentially functional at physiological pH.
6) In vitro release of Insulin from the Boronate- AVTs
A small volume (500 mL) of the agglomerates was loaded inside
a 100 K MWCO dialysis membrane (Spectrum Laboratories, Inc.,
Rancho Dominguez, CA) and dialyzed against PBS at pH 7.4 for
60 mins prior to cleaving with glucose to monitor the passive
diffusion of insulin without trigger. This was followed by addition
of glucose solution to the agglomerates inside the membrane at
regular intervals to cleave the AVTs and trigger the release of
insulin. Aliquots were removed from the external phase every
15 mins and insulin concentration was assayed by reading the
absorbance at 214 nm.
The assay was continued for several hours to verify a halt in
release of encapsulated insulin.
Supporting Information
Figure S1 4-aminocarbonylphenylboronic acid tethered
to Boc-n-propylamine linker.
(TIF)
Figure S2 4-aminocarbonylphenylboronic acid tethered
to n-propylamine linker.
(TIF)
Figure S3 4-aminocarbonylphenylboronic acid tethered
to DSPE-PEG-COOH.
(TIF)
Scheme S1 General scheme for the preparation of
PEGylated lipid-boronic acid conjugates.
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Scheme S2 General scheme for the preparation of
PEGylated lipid-sugar conjugates.
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